相关实验视频
Updated: Jul 2, 2025

04:26
Postoperative Ileus Murine Model
Published on: July 12, 2024
603
可能是博尔特佐米布诱导的麻性乳房病例
Nikhil Aravind1, Niveditha Krishnappa1, Nusrat Shafiq1
1Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
BMJ case reports
|February 21, 2024
概括
多发性骨髓瘤治疗的博特佐米布 (Bortezomib) 可能导致急性肠道阻塞. 这种罕见的副作用需要在接受化疗的患者中仔细监测和管理.
科学领域:
- 在瘤学瘤学.
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 多发性骨髓瘤是一种血液性恶性瘤,用化疗方案治疗.
- 博尔特佐米布是一种蛋白酶体抑制剂,通常用于多发性骨髓瘤治疗.
- 化疗可以产生各种胃肠道副作用,包括罕见但严重的并发症.
研究的目的:
- 报告一种罕见的急性肠道阻塞病例,该病例发生在接受博特佐米布,环胺和德克萨米他治疗的多发性骨髓瘤患者身上.
- 调查博特佐米布在引起这种不良事件中的潜在作用.
- 审查关于管理博特佐米布诱导的胃肠道毒性的文献.
主要方法:
- 一个多发性骨髓瘤患者的病例报告.
- 对急性肠道阻塞的临床表现和诊断工作.
- 手术干预和随后的患者结局.
- 关于博雷佐米布的副作用和肠道阻塞的文献综述.
主要成果:
- 患者在开始服用博雷佐米布,环胺和德克萨米后一周出现了急性肠道阻塞.
- 探索性腹腔切除术没有发现阻塞的机械原因.
- 患者患上了败血症,并最终死亡.
- 波尔特佐米布被怀疑是肠道阻塞的致病剂.
结论:
- 在多发性骨髓瘤患者中,伯特佐米布可能与急性肠道阻塞的风险有关.
- 早期识别和适当的治疗对于在博特佐米布治疗期间发生的胃肠道不良事件至关重要.
- 需要进一步的研究来阐明机制,并优化这种罕见的副作用的管理.
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
164
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
164
Drugs for Treatment of Diarrhea-Predominant IBS
170
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
170
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
202
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
202
Skeletal Muscle Relaxants: Adverse Effects
372
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
Unlike...
372
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
1.8K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
1.8K
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
199
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
199

